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ORIGINAL ARTICLE
Increased serum levels of sortilin are associated with depression
and correlated with BDNF and VEGF
HN Buttenschøn1,2, D Demontis2,3, M Kaas4, B Elfving1, S Mølgaard4, C Gustafsen4, L Kaerlev5,6, CM Petersen4, AD Børglum2,3,
O Mors2,7 and S Glerup4
Neurotrophic factors have been investigated in relation to depression. The aim of the present study was to widen this focus to
sortilin, a receptor involved in neurotrophic signalling. The serum sortilin level was investigated in 152 individuals with depression
and 216 control individuals, and eight genetic markers located within the SORT1 gene were successfully analysed for association
with depression. Genotyping was performed using the Sequenom MassARRAY platform. All the individuals returned a questionnaire
and participated in a semi-structured diagnostic interview. Sortilin levels were measured by immunoassay, and potential
determinants of the serum sortilin level were assessed by generalized linear models. Serum levels of brain-derived neurotrophic
factor (BDNF) and vascular endothelial growth factor (VEGF) were measured in previous studies. We identiﬁed a signiﬁcant increase
of serum sortilin levels in depressed individuals compared with controls (P= 0.0002) and signiﬁcant positive correlation between
serum sortilin levels and the corresponding levels of BDNF and VEGF. None of the genotyped SNPs were associated with
depression. Additional analyses showed that the serum sortilin level was inﬂuenced by several other factors. Alcohol intake and
body mass index, as well as depression, serum BDNF and serum VEGF were identiﬁed as predictors of serum sortilin levels in our
ﬁnal multivariate model. In conclusion, the results suggest a role of circulating sortilin in depression which may relate to altered
activity of neurotrophic factors.
Translational Psychiatry (2015) 5, e677; doi:10.1038/tp.2015.167; published online 10 November 2015
INTRODUCTION
Depression is a common complex mental disorder and a
worldwide leading cause of disability.1 The aetiology of depression
is not fully understood, but it has been found to be moderately
heritable.2 The identiﬁcation of peripheral biomarkers for depres-
sion is obviously of great clinical relevance and has the potential
to improve diagnosis, treatment and prognosis. Several
hypothesis-driven efforts have been made to identify trait and
state biomarkers, and the search for peripheral biomarkers of
depression has mainly been driven by the monoaminergic, the
immune-inﬂammatory and the neuroendocrine hypothesis.3 Since
the ﬁrst paper reporting differences in serum brain-derived
neurotrophic factor (BDNF) levels between depressed individuals
and healthy controls,4 the hypothesis of a dysregulation in the
neurotrophin system in depression has also been investigated.
Although neurotrophic factors remain exciting peripheral biomar-
ker candidates, we ﬁnd it relevant to widen the focus to their
receptors as well.
Sortilins, also known as the Vsp10-domain receptors are unique
sorting and signalling receptors expressed in the nervous system.
This receptor family includes ﬁve receptors: sortilin, SorLA and
SorCS1-3.5 Members of the sortilin family have been identiﬁed as
potential neuronal disease genes, for example, SORL1 has been
associated with Alzheimer’s disease6 and SORCS2 with bipolar
disorder and attention deﬁcit/hyperactivity disorder.7–9 Sortilins
binds a number of ligands through the 700 amino acid
extracellular Vsp10-domain.10,11 The majority of known sortilin
binding partners are related to lipid metabolism and to
neurotrophic factor signalling as reviewed by Glerup et al.5 Sortilin
is encoded by the SORT1 gene located on chromosome 1p13.3
(ref. 11) and has an important role in regulating BDNF activity.12–14
It has long been known that sortilin can form a complex with the
p75 neurotrophin receptor (p75NTR) and proBDNF to induce
apoptosis,12 and likewise, a more recent study suggests that
sortilin and p75NTR are involved in trophic signalling by mature
neurotrophins.14 The extracellular domain of sortilin (soluble
sortilin) is released in both a constitutive and regulated manner
by proteolysis from the surface of neuronal and other cell
types.13,15,16 The function of soluble sortilin is unclear but it has
been found to inhibit the conversion of proBDNF into mature
BDNF by plasmin and to protect neurons from the apoptotic
properties of proBDNF.12 Furthermore, a recent report describes
that released soluble sortilin forms a complex with the BDNF
receptor TrkB and the EGF receptor and that this ternary complex
is internalized and subsequently released again in exosomes.17
Soluble sortilin can be detected in serum18,19 and plasma,13 and
has been found to correlate well with sortilin mRNA levels in the
brain.20 The source of circulating sortilin is unclear, but it is
expressed by most tissues including blood cells and platelets.5,13
On the basis of the above, we speculated that sortilin has a role
in depression. Thus, we investigated genetic variants located
within the SORT1 gene and measured serum sortilin levels in 152
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cases with depression and 216 control individuals. We also
investigated the correlation between serum sortilin levels and
BDNF in addition to the correlation between serum sortilin
and vascular endothelial growth factor A (VEGF) levels, another
neurotrophic factor suggested to have a role in the pathophysiol-
ogy of depression.21 A secondary aim of the study was to identify
determinants inﬂuencing the serum sortilin level and to build a
multivariate model.
MATERIALS AND METHODS
Population
One-hundred and ﬁfty-two individuals with depression according to the
ICD-10 diagnostic criteria for research and 216 screened control individuals
were included in the study. The subjects were all part of the Danish PRISME
study22,23 where they returned a completed questionnaire, and partici-
pated in a semi-structured diagnostic interview.24 Details on the study
sample are presented elsewhere.25,26 The following socio-demographic
variables, lifestyle indicators, and health indicators were obtained from the
questionnaire: smoking (current smoker/previous smoker/never smoker),
antidepressant treatment (yes/no), previous depressive episodes (yes/no),
previous diagnosis of other psychiatric disorders (yes/no), physical activity
(⩽ /44 h per week) and alcohol intake (female: ⩽ /420 g per day and
male: ⩽ /430 g per day). Age and gender were derived from the personal
identiﬁcation number assigned to all live-born children and stored in the
Danish Civil Registration System.27 Body mass index (BMI) was calculated
from the measured height and weight obtained at the clinical interview. A
Danish translation of a brief version of the List of Threatening Experiences
Questionnaire28,29 was used to record nine stressful life events up to
6 months before completion of the questionnaire. Each stressful life event
was rated on a four-point scale severity with a rating of not present, mild,
moderate and severe. In this analysis, only moderate and severe events
were counted. Although the original List of Threatening Experiences
Questionnaire consists of 12 events, we only included nine events. Two
questions from the original List of Threatening Experiences Questionnaire
were combined into a single item (these were: ‘did you have a separation
due to marital difﬁculties?’ and ‘did you break off a steady relationship?’
which were combined into ‘did you have a separation due to marital
difﬁculties or break off a steady relationship?’). Two questions in relation to
unemployment were excluded from the present study as all the
participants were either municipal or hospital employees within large
public service workplaces in a Danish county. Case–control status
(diagnosis of depression) was obtained from the clinical interview
according to the ICD-10 diagnostic criteria.30
All cases and controls gave written informed consent and the study was
approved by the Danish Data Protection Agency (2006-41-7032) and the
Regional Ethics Committee (RRS 2006-1028 (2747-06)) in Denmark.
Serum measurements
Blood for serum samples was collected in anticoagulant-free tubes
(Terumo, Venosafe, VF-109SP, Prague, Czech Republic) between 0900 h
and 1500 h and centrifuged (1550 g, 10 min, 4 °C) within 24 h. The
supernatant was stored in aliquots at −80 °C. Serum sortilin levels were
measured blinded for case and control status by sortilin-speciﬁc enzyme-
linked immunosorbent assay as previously described in Gustafsen et al.18
This assay speﬁcially detects sortilin and not the related receptors SorCS2
and SorLA at a sensitivity of ~ 0.1 ngml− 1 as shown in Supplementary
Figure 1. In brief, 96-well plates (Nunc Maxisorp, Thermo Scientiﬁc,
Roskilde, Denmark) were coated with 10 μgml− 1 rabbit anti-sortilin (5438)
diluted in 100mM NaHCO3, pH 9.8. Wells were blocked in 2% bovine serum
albumin and samples were diluted in phosphate-buffered saline contain-
ing 0.05% Tween20 and 1% bovine serum albumin. Puriﬁed sortilin
extracellular domain was used for standard dilution series.31 Mouse anti-
human sortilin monoclonal F11 was used for detection (1 μgml− 1)
followed by HRP-conjugated rabbit anti-mouse secondary antibodies
(1:2000, P0260, Dako, Glostrup, Denmark). For additional information on
the use of these antibodies, please see the online database www.pabmabs.
com. Serum levels of BDNF and VEGF were measured previously in the
same individuals using immunoassays from R&D Systems (Minneapolis,
MN, USA) and the determination was processed according to the
manufacturer’s speciﬁcations.25,26 The same batch numbers was used for
the entire experiments and the standard curves and the samples were run
in duplicates. The absorbances were measured at 450 nm with wavelength
correction set to 540 nm (EL 800 Universal Microplate Reader, Bio-Tek
Instruments, Winooski, VT, USA). Serum samples for VEGF measurements
were analysed undiluted to be within the range of the standard curves
whereas serum samples for BDNF were diluted 1:75 to be within the range
of the standard curves. In general, duplicate determinations of absorbancy
with an intra-assay variance above 5% were determined again another day
and the non-reliable measure discarded. The mean value of the duplicates
was used in the statistical analyses.
Genotyping
Single-nucleotide polymorphisms (SNPs) selected for genotyping were
identiﬁed from HapMap data (http://www.hapmap.org, version 27 dbSNP
126 (NCBI build 36)) using the tagger selection algorithm in Haploview
(pair-wise tagging function, r2 threshold= 0.8).32 Genotyping was per-
formed using the Sequenom MassARRAY platform. In total, 10 SNPs
located within the gene region of the SORT1 gene were selected for
genotyping, however, one SNP failed, and one SNP was excluded from
further analysis owing to a minor allele frequency below 0.005. Thus, after
quality control, eight SNPs with nice cluster plots were left for analyses.
Chronic alcohol treatment of mice
To determine the effect of alcohol treatment on sortilin levels in the
hippocampus, a group of experimentally naive C57BL/6 J male mice
(n=10, 12–16 weeks of age) was subjected to a 4-week forced drinking
regimen. During the ﬁrst week, animals were given a choice between
water and an alcohol solution in water (2% for the ﬁrst 3 days, then 5% for
4 days). Subsequently, the water bottle was removed and the mice were
provided 5% alcohol in water as the sole drinking source for 3 days. This
was then increased to 10% for 4 days and ﬁnally 20% for the remaining
2 weeks. At the end of the 4 weeks, the mice were killed and their
hippocampi removed. The levels of sortilin were subsequently analysed by
western blotting and compared with those of naive mice.
Fluoxetine treatment of mice
For chronic antidepressant treatment, the experiments were carried out as
described in Di Lieto et al.33 Three wild-type males aged 52 weeks were
used in each group. The mice had free access to either tap water or tap
water with 0.08mgml− 1 addition of ﬂuoxetine (Sigma-Aldrich #1279804)
for 21 days. On the ﬁnal day of treatment, the animals were euthanized by
cervical dislocation and the hippocampus and prefrontal cortex samples
were rapidly dissected. The samples were hereafter homogenized and
lysed in TNE buffer.
Statistical analyses
The software PLINK34 was used to perform quality control of the genotypes
and to calculate the trend for association between the SNP alleles and
depression.
Multiple linear regression models were used to assess independent
determinants of the serum sortilin level, and testing was performed using
likelihood-ratio statistics. Natural logarithm transformation was used to
normalize the distribution of the sortilin levels. The analyses were
conducted using Stata 13 (StataCorp, College Station, TX, USA) and a
P-value of o0.05 was considered to be statistically signiﬁcant. None of the
analyses were corrected for multiple testing. Univariate linear regression
analyses using socio-demographic variables, health indicators, lifestyle
indicators and genotypes to assess independent variables of serum sortilin
were performed. Likewise, we performed exploratory tests for some
potentially relevant two-way interactions. We considered the interaction
between the signiﬁcant main effects and between the main effects and
sex. Correlations between the serum measurements were calculated using
the Spearman’s rank correlation coefﬁcient. Differences between sexes and
between cases and controls in serum measurements, socio-demographic
data, lifestyle indicators and health indicators were evaluated with the
Wilcoxon two-sample rank-sum test for continuous variables and χ2 test for
categorical variables.
RESULTS
The case group comprised 25 males and 127 females, and the
control group comprised 46 males and 170 females. No signiﬁcant
differences in serum sortilin, BDNF or VEGF levels between sexes
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were observed (Table 1). Likewise, no signiﬁcant differences were
observed among males and females when analysing the cases and
controls separately (not shown). A signiﬁcantly higher mean
serum sortilin level was observed in depressed individuals
compared with controls (Table 1, Supplementary Figure 2). A
further exploration of this showed signiﬁcantly higher serum
sortilin level in female cases compared with female controls. The
same tendency was observed in male cases compared with male
controls; however, the difference was not signiﬁcant (not shown).
We previously reported signiﬁcantly higher serum BDNF and
VEGF levels in cases compared with controls.25,26 However, the
present study sample includes fewer individuals than the previous
studies, and, for transparency, the medians and means for serum
BDNF and VEGF are therefore presented in Table 1.
Additional sample characteristics are presented in Table 2. We
observed a signiﬁcant difference between cases and controls in
hours of physical activity, smoking habits, previous depressive
episodes, previous diagnoses with other mental disorders,
antidepressant treatment and numbers of experienced stressful
life events (Table 2). We also observed a signiﬁcant difference
between males and females in the mean age (P= 0.005),
BMI values (P= 0.006) and alcohol consumption (P= 0.03;
Supplementary Table 1).
Within individual, serum levels of sortilin were positively
correlated with serum BDNF and VEGF (r= 0.28, Po0.0001 and
r= 0.24, Po0.0001, respectively; Figure 1).
Regression model
To understand which factors might inﬂuence the serum sortilin
concentration, we performed univariate analyses of socio-
demographic determinants, lifestyle indicators, health indicators
and genotypes (Table 3). The regression analyses showed that the
mean serum sortilin concentration increased signiﬁcantly with
increasing age, BMI, serum VEGF and serum BDNF levels and with
high alcohol intake, depression and previous depressive episodes.
However, no association between the serum sortilin level and
previous depressive episodes was observed in the control group.
The mean serum sortilin concentration decreased signiﬁcantly in
individuals with the CT genotype of rs11581665 compared with
the CC genotype and in individuals with the AG genotype of
rs3768497 compared with the GG genotype. No signiﬁcant
differences were observed between the individuals homozygous
for the CC genotype compared with the TT genotype for
rs11581665 and between individuals homozygous for the GG
genotype compared with the AA genotype for rs3768497. Further
exploration of these ﬁndings also showed that the signiﬁcantly
lower mean serum sortilin levels observed for heterozygous
individuals were only observed in the control group. The mean
serum sortilin levels depending on the rs11581665 and rs3768497
genotype are presented in the Supplementary Table 2. BDNF was
the most signiﬁcantly associated variable in the univariate
analyses and explaining 5% of the variability of the serum sortilin
level. The other signiﬁcantly associated variables explained 1–5%
of the variability each.
Multiple regression model
To build a model of the serum sortilin level, we used a stepwise
forward inclusion and backward elimination procedure, and the
ﬁnal model contained ﬁve signiﬁcant determinants: depression,
serum BDNF, serum VEGF, alcohol and BMI. None of the tested
two-way interactions were statistically signiﬁcant and thus not
included in the ﬁnal model. Regression coefﬁcients from the ﬁnal
multiple regression model are shown in Table 4. The ﬁnal
regression model shows that compared with controls and
adjusting for serum levels of BDNF and VEGF, BMI and alcohol
intake, the mean sortilin level is signiﬁcantly increased in
depressed individuals. Compared with the individuals with an
alcohol intake ⩽ 20 g per day and ⩽ 30 g per day for females and
males, respectively, and adjusting for serum levels of BDNF and
VEGF, BMI and depression, the mean sortilin levels are signiﬁcantly
increased in individuals with an alcohol intake above 20 and 30 g
per day for females and males, respectively. In addition, the mean
serum sortilin levels increases for every unit increase in serum
BDNF, VEGF and BMI, respectively, when adjusting for the above-
mentioned variables.
Effect of alcohol and antidepressants on sortilin in the central
nervous system
To further understand how factors associated with increased
serum levels of soluble sortilin affects sortilin protein levels in the
central nervous system (CNS), we conducted a series of mouse
experiments. Exercise and diet have previously been reported to
affect sortilin levels in the brain and liver, respectively.35–37
However, we here observed no effect of long-term alcohol
drinking or administration of the antidepressant ﬂuoxetine on
sortilin protein levels in the mouse CNS (Supplementary Figure 3).
Table 1. Medians and means for sortilin, BDNF and VEGF
Median (95 % CI) Mean (std) P-value*
Male (n= 71) Female (n= 297) Male (n= 71) Female (n= 297)
Sortilin (ngml− 1) 24 (17–36) 24 (15–34) 25 (6) 24 (6) 0.33
Male (n= 70) Female (n= 296) Male (n= 70) Female (n= 296)
BDNF (pgml− 1) 29 972 (20 819–43 312) 29 717 (19 742–42 980) 30 379 (6644) 30 267 (7148) 0.83
Male (n= 69) Female (n= 286) Male (n= 69) Female (n= 286)
VEGF (pgml− 1) 259 (76–720) 310 (87–735) 324 (239) 344 (207) 0.19
Case (n= 152) Control (n= 216) Case (n= 152) Control (n= 216)
Sortilin (ngml− 1) 26 (17–40) 23 (15–33) 26 (7) 23 (6) 0.0002
Case (n= 151) Control (n= 215) Case (n= 151) Control (n= 215)
BDNF (pgml− 1) 30 817 (21 088–44 732) 29 225 (19 291–41 417) 31 228 (7388) 29 628 (6735) 0.04
Case (n= 150) Control (n= 205) Case (n= 150) Control (n= 205)
VEGF (pgml− 1) 361 (107–872) 245 (75–661) 407 (230) 290 (186) o0.0001
Abbreviations: BDNF, brain-derived neurotrophic factor; CI, conﬁdence interval; VEGF, vascular endothelial growth factor.
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Table 2. Sample characteristics (n= 368)
Sociodemographics Details Statistics
Case Control Total P-value
Male (%) 25 (16) 46 (21)
Female (%) 127 (84) 170 (79)
Mean age in years (s.d.) 47.1 (9.4) 46.3 (10.2) 46.7 (9.8) 0.55a
Lifestyle indicators
Physical activity (70) 0.022b
44 h per week (%) 52 (41.3) 94 (54.6) 146 (49.0)
⩽ 4 h per week (%) 74 (58.7) 78 (45.4) 152 (51.0)
Smoking (1) 0.011b
Smoking (%) 41 (27) 32 (14.9) 73 (19.9)
Previous smoker (%) 53 (34.9) 77 (35.8) 130 (35.4)
Never smoker (%) 58 (38.1) 106 (49.3) 164 (44.7)
BMI (2) kg/m2 (s.d.) 26.0 (5.4) 25.3 (4.3) 25.6 (4.8) 0.40a
Alcohol (3) 0.131b
⩽ 20/30 g per day (%) 138 (90.8) 202 (94.8) 340 (93.2)
420/30 g per day (%) 14 (9.2) 11 (5.2) 25 (6.8)
Health indicators
Depression
Mild depression (%) 56 (36.8)
Moderate depression (%) 70 (46.1)
Severe depression (%) 26 (17.1)
Previous depressive episodes (11) o0.001b
Previous depressive episodes (%) 79 (54.9) 26 (12.2) 105 (29.4)
No previous depressive episodes (%) 65 (45.1) 187 (87.8) 252 (70.6)
Previous diagnosis with other mental disorders (26) o0.001b
Previous diagnosis with other mental disorders (%) 14 (10.7) 1 (0.5) 15 (4.4)
No previous diagnosis with other mental disorders (%) 117 (89.3) 210 (99.5) 327 (95.6)
Antidepressant treatment (66) o0.001b
No antidepressant treatment (%) 102 (70.3) 152 (96.8) 254 (84.1)
Antidepressant treatment (%) 43 (29.7) 5 (3.2) 48 (15.9)
SLEs o0.001b
No experienced SLEs 63 (41.5) 135 (62.5) 198 (53.8)
One experienced SLE 42 (27.6) 58 (26.9) 100 (27.2)
Two or more experienced SLEs 47 (30.9) 23 (10.6) 70 (19.0)
Abbreviations: BMI, body mass index; SLE, stressful life event. aWilcoxon two-sample rank-sum test (Mann–Whitney test). bChi square test. Number of missing
individuals are listed in bold parenthesis in the ﬁrst column.
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Figure 1. Scatter plots illustrating correlations between the serum sortilin level and serum levels of BDNF and VEGF, respectively. BDNF, brain-
derived neurotrophic factor; VEGF, vascular endothelial growth factor.
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Genetic analyses
None of the successfully genotyped SNPs showed evidence
of association with depression in the single SNP analyses
(Supplementary Table 3).
DISCUSSION
To the best of our knowledge, the present study comprising 368
individuals is so far the most comprehensive study of sortilin and
depression. The relationship between depression and serum levels
of sortilin and the association between depression and genetic
markers located within the SORT1 gene were investigated.
Furthermore, the correlation between serum sortilin levels and
serum BDNF and VEGF levels, respectively, were investigated. A
secondary aim of our study was to identify potential determinants
of serum sortilin levels and to build a multivariate model. Finally,
we addressed whether high alcohol consumption and antide-
pressant treatment affects sortilin expression in the mouse CNS.
In summary, we observed a signiﬁcant increase in serum sortilin
level in depressed individuals compared with controls and signiﬁcant
correlations between serum levels of sortilin levels and the serum
levels of BDNF and VEGF, respectively. None of the genotyped SNPs
showed evidence of association with depression; however, the level
Table 3. Univariate analyses
Sociodemographics and lifestyle Details Linear regression
Coefﬁcient Test P-value
Male 0.04 (−0.03;0.11) 1.18 0.24
Age 0.004 (0.001;0.006) 2.78 0.006
Alcohol intake 420 g per day for females
and 430 g per day for males
0.13 (0.02;0.24) 2.41 0.02
Smoking Present smoker 0.04 (−0.03;0.11) 1.02 0.31
Previous smoker 0.004 (−0.06;0.06) 0.13 0.9
BMI 0.01 (0.003;0.01) 2.98 0.003
Physical activity 44 h per week − 0.06 (−0.12;0.003) − 1.88 0.061
One experienced SLEs − 0.01 (−0.07;0.05) − 0.26 0.8
Two or more experienced SLEs − 0.04 (−0.11;0.03) − 1.05 0.29
Health indicators
Depression 0.10 (0.05;0.16) 3.84 o0.001
Mild 0.10 (0.03;0.18) 2.73 0.007
Moderate 0.14 (0.08;0.21) 4.13 o0.001
Severe − 0.004 (−0.11;0.10) − 0.08 0.93
Previous depressive episodes 0.06 (0.001;0.12) 2.00 0.05
Previous diagnosed with other mental disorders − 0.01 (−0.15;0.13) − 0.16 0.88
Antidepressant treatment 0.07 (−0.01;0.15) 1.67 0.1
Serum measurements
Serum VEGF 2e− 4 (1e− 4;4e− 4) 4.21 o0.001
Serum BDNF 9e− 6 (5e− 6;1e− 5) 4.64 o0.001
Genotypes
rs11581665 CT genotype − 0.09 (−0.16;− 0.03) − 2.84 0.005
TT genotype − 0.02 (−0.19;0.14) − 0.27 0.79
rs12037569 GT genotype 0.02 (−0.05;0.08) 0.49 0.63
TT genotype 0.08 (−0.10;0.27) 0.9 0.37
rs17585355 CA genotype 0.01 (−0.07;0.10) 0.34 0.74
CC genotype 0.10 (−0.26;0.47) 0.57 0.57
rs17646665 GA genotype 0.04 (−0.03;0.11) 1.07 0.29
GG genotype 0.31 (−0.20;0.82) 1.18 0.24
rs3768497 AA genotype − 0.05 (−0.14;0.04) − 1.07 0.29
AG genotype − 0.06 (−0.12;− 0.007) − 2.22 0.027
rs413582 CT genotype − 0.01 (−0.08;0.05) − 0.39 0.7
TT genotype 0.01 (−0.07;0.09) 0.26 0.8
rs464218 CC genotype − 0.04 (−0.12;0.04) − 0.97 0.33
CT genotype − 0.03 (−0.09;0.03) − 0.9 0.37
rs7536292 CC genotype 0.11 (−0.05;0.28) 1.35 0.18
CT genotype − 0.0005 (−0.06;0.06) − 0.02 0.99
rs6265 (val66met) AA genotype 0.006 (−0.11;0.12) 0.1 0.92
GA genotype 0.05 (−0.01;0.10) 1.55 0.12
Abbreviations: BDNF, brain-derived neurotrophic factor; BMI, body mass index; SLE, stressful life event; VEGF, vascular endothelial growth factor. P-values for
signiﬁcantly associated variables are shown in bold.
Table 4. Multiple regression—the ﬁnal model (n= 349)
Coefﬁcient (95% CI) s.e. Test P-value
Depression 0.071 (0.017;0.13) 0.028 2.6 0.01
Serum BDNF 7.3e− 6 (3.6e− 6;1.1e− 5) 1.9e− 06 3.8 o0.001
Serum VEGF 1.5e− 4 (2.2e− 5;2.8e− 4) 6.6e−05 2.3 0.022
Alcohol 0.14 (0.038;0.25) 0.053 2.7 0.007
BMI 0.0071 (0.0016;0.013) 0.0028 2.6 0.011
Constant 2.7 (2.5;2.8) 0.087 31 o0.001
Abbreviations: BDNF, brain-derived neurotrophic factor; BMI, body mass
index; CI, conﬁdence interval; VEGF, vascular endothelial growth factor.
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of serum sortilin was signiﬁcantly associated with two SNPs. The
univariate regression analyses of factors inﬂuencing the serum sortilin
level showed that the mean concentration of serum sortilin increased
signiﬁcantly with increasing age, BMI, serum VEGF and serum BDNF
levels in addition to high alcohol intake and previous depressive
episodes. Our ﬁnal multiple regression model included ﬁve predictors:
depression, serum BDNF, serum VEGF, alcohol intake and BMI. None
of the analyses were corrected for multiple testing, however.
Only a few other studies have investigated serum sortilin levels
in depression. In accordance with our study, Zhou et al. also found
a signiﬁcantly higher sortilin level in 40 depressed individuals
compared with 50 controls.19 Interestingly, a recent study
investigating differentially expressed proteins in 12 depressed
individuals after electroconvulsive therapy observed a signiﬁcant
decrease in serum sortilin level following treatment.38
Interestingly, high sortilin levels was associated with mild and
moderate depression, but not with severe depression. Likewise, no
association between serum BDNF levels and severe depression or
between serum VEGF levels and severe depression were observed
in our previous studies of the same individuals.25,26 Our study only
included 26 individuals with a severe depression compared with
56 and 70 individuals with a mild and moderate depression,
respectively. Our ﬁnding could thus be a result of low power to
detect association in this subgroup of cases.
In the univariate analyses, we observed no association between
serum sortilin levels and antidepressant treatment; however, only 48
individuals (16%) reported to receive antidepressant treatment, of
which 43 were cases and ﬁve were controls. Sub-analyses in patients
only, likewise, showed no signiﬁcant differences in the serum sortilin
level between depressed individuals receiving antidepressant
treatment compared with those that did not receive treatment.
Our data demonstrate that apart from depression, several other
factors may inﬂuence the serum sortilin level. Of note, both BDNF
and VEGF display signiﬁcant correlation with sortilin, suggesting that
altered neurotrophic factor activity may affect sortilin expression and/
or shedding or vice versa. Most studies investigating the serum BDNF
levels (including our previous studies25,26) have used commercial kits
that do not differentiate mature BDNF from proBDNF. In future
studies, it would be relevant to investigate whether mature BDNF
and proBDNF are differentially correlated to sortilin.
The observed association between sortilin and BMI is supported
by the fact that sortilin is also expressed in adipose tissue and in
the liver, and is involved in lipid metabolism.5 Indeed, soluble
sortilin in serum was previously found to correlate positively with
PCSK9, a potent negative regulator of lipoprotein particle
receptors.18 Interestingly, western-type diet and administration
of saturated fatty acids resulted in posttranslational downregula-
tion of hepatic sortilin without affecting mRNA levels,35,36 while a
recent study reported that 4 months of moderate treadmill
running signiﬁcantly reduced sortilin protein levels in the mouse
cortex,37 altogether suggesting that a combination of diet and
exercise may have marked and potentially opposite effects on the
levels of circulating soluble sortilin and full-length sortilin in liver
and brain, respectively. Likewise, we observed that a high intake of
alcohol was associated with an increase in the mean sortilin
concentration in serum although long-term alcohol administration
had no effects on full-length sortilin protein levels in the mouse
hippocampus. Interestingly, although still a matter of debate,
BDNF has been hypothesized to be involved in ethanol–induced
neurodegeneration in the adult brain, and high alcohol intake has
been associated with lower serum BDNF levels.39,40 Depression is
furthermore known to predispose for alcohol abuse.41 As
information on alcohol intake in the present study was obtained
from the questionnaire, the risk of biased reporting is, however,
increased. Potentially, several other biological and environmental
factors not considered in this study might inﬂuence the serum
sortilin level. Storage time of the samples and diurnal variation
may, for example, affect the serum sortilin levels. Given the stable
structure of sortilin,5 we have, however, no reason to believe that
the generation of soluble sortilin varies dramatically on a daily and
monthly basis, but future studies should address the half-life and
stability of soluble sortilin in the circulation. Likewise, unpublished
data indicate that sortilin levels are not affected to any major
extent by variation in sampling and processing times or by
multiple freeze–thaw cycles. However, future systematic studies
on this issue are warranted.
The present study was limited by the data collected in the
PRISME study and thus no power calculations were performed
before initiation of the study.
None of the genotyped SNPs were associated with depression. This
ﬁnding is supported by a large and comprehensive genetic study for
depression including more than 18 000 individuals in the discovery
phase and more than 57 000 individuals in the replication phase,
found no evidence of association between depression and the
chromosome region comprising SORT1.42 Interestingly, however, the
intronic SNP, rs11581665, was signiﬁcantly associated with serum
sortilin levels. We observed a signiﬁcantly higher serum sortilin level in
individuals homozygous for the major allele (C-allele) compared with
heterozygous individuals. Likewise, the mean serum sortilin level in
individuals heterozygous for another intronic SNP, rs3768497, was
signiﬁcantly decreased compared with individuals homozygous for
the major allele (G-allele). Analyses of the cases and controls sepa-
rately (rs11581665 and rs3768497) revealed a signiﬁcant difference in
the serum sortilin level in the control group only. According to the
NCBI eQTL Browser and the Genotype-Tissue Expression project, none
of these SNPs are known eQTLs. Thus the relevance of these ﬁndings,
if any, remains to be elucidated. Larger studies on serum sortilin levels
and these genotypes are therefore warranted.
How increased levels of soluble sortilin in serum contribute to the
pathophysiology of depression still remains elusive. Studies in rats
have shown that sortilin mRNA was two-fold reduced in the
hippocampus of rats resistant to the experimental depression
paradigm learned helplessness compared with non-resistant rats,43
indicating a potential correlation between sortilin expression in the
CNS and susceptibility to depression. Of note, our present studies
show that antidepressant treatment itself did not alter sortilin
protein levels in the hippocampus or cortex of mice. Hence, the
increased soluble sortilin in serum of depressed patients may mirror
abnormal CNS expression as a consequence of depression itself but
not treatment. Furthermore, abnormal amounts of soluble sortilin
likely perturb several neurotrophic factor systems. Indeed, soluble
sortilin has been suggested to function as a decoy receptor for
progranulin, thereby promoting its neurotrophic activity.44 On the
other hand, soluble sortilin inhibits proteolysis of proBDNF and the
generation of mature BDNF.12
CONCLUSION
In conclusion, our results suggest a role of circulating sortilin in
depression and that the serum sortilin level is inﬂuenced by
several factors, including neurotrophic factor activity. Owing to
the large amount of information, this is, to the best of our
knowledge, the most comprehensive study of sortilin in depres-
sion. However, further investigations are needed to replicate our
ﬁndings. Studies including additional factors that potentially could
inﬂuence the sortilin level in addition to longitudinal studies of
sortilin in depression are also warranted.
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